Why is Brawn Biotech falling/rising?

As of 04-Jul, Brawn Biotech Ltd is currently priced at 19.99, reflecting a slight decrease of 0.01, or 0.05%. The stock has recently outperformed its sector by 7.66%, although it has experienced a trend reversal after five consecutive days of gains. Despite trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, the stock faces significant challenges, including operating losses and a weak long-term fundamental strength. Over the past year, Brawn Biotech has underperformed the market, generating a return of -27.28% compared to the BSE500's positive return of 2.13%. The company's net sales have declined at an annual rate of -22.97%, and it has a negative EBITDA, indicating ongoing financial difficulties.
In the broader market context, while Brawn Biotech has shown a strong short-term performance with a 21.52% increase over the last month, it remains significantly behind the benchmark, which has gained 3.01% in the same period. The overall market sentiment appears to be more favorable, as evidenced by the Sensex's positive returns. However, the stock's liquidity is adequate, with a delivery volume increase of 47.33% against the 5-day average, suggesting some investor interest despite the underlying financial risks. The combination of weak fundamentals and recent price movements indicates that while there may be short-term gains, the long-term outlook for Brawn Biotech remains precarious.